2021
Reply Systems Approach to Innovating Pretransplantation Mechanical Circulatory Support
Mullan CW, Ahmad T. Reply Systems Approach to Innovating Pretransplantation Mechanical Circulatory Support. JACC Heart Failure 2021, 9: 532. PMID: 34210392, DOI: 10.1016/j.jchf.2021.05.002.Commentaries, Editorials and LettersReply Worse Post-Transplant Survival on Patients Bridged With LVAD in the New Heart Transplant Allocation System?
Mullan CW, Ahmad T. Reply Worse Post-Transplant Survival on Patients Bridged With LVAD in the New Heart Transplant Allocation System? JACC Heart Failure 2021, 9: 533-534. PMID: 34210393, DOI: 10.1016/j.jchf.2021.05.003.Commentaries, Editorials and LettersOutcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation
Guha A, Caraballo C, Jain P, Miller PE, Owusu‐Guha J, Clark KAA, Velazquez EJ, Ahmad T, Baldassarre LA, Addison D, Weintraub NL, Desai NR. Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure 2021, 8: 2866-2875. PMID: 33982867, PMCID: PMC8318466, DOI: 10.1002/ehf2.13362.Peer-Reviewed Original ResearchConceptsAnthracycline-induced cardiomyopathyIschemic cardiomyopathyCardiomyopathy patientsCF-LVADICM patientsLeft ventricular assist device implantationContinuous-flow LVAD implantationHigher major bleeding riskVentricular assist device implantationEnd-stage heart failureMechanically Assisted Circulatory SupportCox proportional hazards modelCF-LVAD implantationAcute kidney injuryMajor bleeding riskAssist device implantationEtiology of cardiomyopathyProportional hazards modelBleeding riskKidney injuryInteragency RegistryLVAD implantationMajor infectionMedian survivalRespiratory supportLeft Ventricular Assist Devices Versus Heart Transplantation for End Stage Heart Failure is a Misleading Equivalency∗
Mullan CW, Sen S, Ahmad T. Left Ventricular Assist Devices Versus Heart Transplantation for End Stage Heart Failure is a Misleading Equivalency∗. JACC Heart Failure 2021, 9: 290-292. PMID: 33795115, DOI: 10.1016/j.jchf.2021.02.004.Commentaries, Editorials and LettersChanges in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy
Mullan CW, Chouairi F, Sen S, Mori M, Clark KAA, Reinhardt SW, Miller PE, Fuery MA, Jacoby D, Maulion C, Anwer M, Geirsson A, Mulligan D, Formica R, Rogers JG, Desai NR, Ahmad T. Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC Heart Failure 2021, 9: 420-429. PMID: 33714748, DOI: 10.1016/j.jchf.2021.01.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultHeart FailureHeart TransplantationHeart-Assist DevicesHumansPolicyRetrospective StudiesTissue DonorsTreatment OutcomeUnited StatesWaiting ListsConceptsDonor heart allocation systemNumber of patientsHeart allocation systemVentricular assist deviceWaitlist survivalAssist deviceNew heart allocation policyLeft ventricular assist deviceAllocation system changePost-transplant mortalityOrgan Sharing databaseOutcomes of patientsPost-transplantation outcomesProportion of patientsTime of transplantContinuous-flow LVADPost-transplantation survivalHeart allocation policyNew allocation systemBaseline recipientStatus 1AHeart transplantationIschemic timeLVAD implantationTransplant list
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomesImpact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement
Stawiarski K, Agboola O, Park J, Geirsson A, Jacoby D, Bellumkonda L, Ahmad T, Chou J, Lee F, Mangi A, Bonde P. Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal 2020, 67: 650-657. PMID: 33074860, DOI: 10.1097/mat.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHeart FailureHeart-Assist DevicesHumansLymphopeniaMaleMiddle AgedProportional Hazards ModelsConceptsAbsolute lymphocyte countCause mortalityLymphopenia groupLeft ventricular assist device patientsVentricular assist device patientsVentricular assist device placementCox proportional hazards modelImpact of lymphopeniaHeart failure populationKaplan-Meier plotsFurther clinical investigationProportional hazards modelLog-rank statisticsDurable LVADPreoperative lymphopeniaLVAD placementLymphocyte countLymphopenic patientsDevice patientsSingle centerPoor outcomePrognostic implicationsALC levelsFailure populationStudy population